NCT03313401 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Ammar DA, Mandava N, Kahook MY
The effects of aflibercept on the viability and metabolism of ocular cells in vitro. Retina. 2013 May;33(5):1056-61. doi: 10.1097/IAE.0b013e31827b646d.
de Oliveira Dias JR, de Andrade GC, Novais EA, Farah ME, Rodrigues EB
Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int J Retina Vitreous. 2016 Feb 1;2:3. doi: 10.1186/s40942-016-0026-y. eCollection 2016
Stewart MW, Rosenfeld PJ
Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008 May;92(5):667-8. doi: 10.1136/bjo.2007.134874. Epub 2008 Mar 20.

Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration: A Pilot Study

Clinical trial NCT03313401 - References